1.Research Progress and Expectation on Modern Fresh Chinese Medicine Preparation
Hui ZHU ; Yuzhen LI ; Yizhou XIE ; Ying YANG ; Hongpeng YU ; Hongqiang LI
World Science and Technology-Modernization of Traditional Chinese Medicine 2018;20(10):1889-1894
In this paper, we reviewed the long history of the use of modern fresh Chinese Medicine (FCM) and summarized the development of fresh Chinese Medicine preparation (MFCMP) in recent years. Combined with domestic and foreign examples, the characteristics the technology and preparations of MFCMP are explained. Meanwhile, as for the development of FCM and MFCMPs, the problems faced and feasible solutions are put forward. Finally, based on China.s national conditions, the development trend of MFCMPs is prospected.
2.Application and Safety Evaluation of DEHP in PVC Medical Devices.
Yue WANG ; Xin XIE ; Hongqiang JIANG ; Jun WANG
Chinese Journal of Medical Instrumentation 2018;42(4):293-295
DEHP is largely used in soft PVC products as the plasticizer, which is also widely applied in medical devices. Due to its potential and widespread toxicity and medical devices' specific use, the safety of DEHP's application in medical devices has received extensive attention. In this paper, a comprehensive review of the application and potential toxicity of DEHP in PVC medical devices is made on the basis of the research results all over the world. Besides, the safety evaluation in medical devices is discussed and some possible coping strategies are explored.
Diethylhexyl Phthalate
;
adverse effects
;
Equipment Safety
;
Equipment and Supplies
;
adverse effects
;
Plasticizers
;
adverse effects
;
Polyvinyl Chloride
3.A novel mutation of GLI3 gene underlying synpolydactyly in a family.
Ranran KANG ; ; Sexin HUANG ; Jie LI ; Yang ZOU ; Peiwen XU ; Ming GAO ; Lijuan WANG ; Hongqiang XIE ; Junhao YAN ; Yuan GAO
Chinese Journal of Medical Genetics 2017;34(4):490-493
OBJECTIVETo detect mutation of GLI3 gene in a family affected with autosomal dominant synpolydactyly.
METHODSGenomic DNA was extracted from peripheral blood samples from members of the family and 100 unrelated healthy controls. Potential mutation was screened by next-generation sequencing and confirmed by Sanger sequencing.
RESULTSA heterozygous frameshift mutation c.480dupC was identified in the GLI3 gene among all patients from the family. The same mutation was not found in unaffected family members and the 100 healthy controls.
CONCLUSIONThe c.480dupC of the GLI3 gene probably underlies the synpolydactyly in this family.
Adolescent ; Adult ; Amino Acid Sequence ; Female ; Humans ; Male ; Middle Aged ; Mutation ; genetics ; Nerve Tissue Proteins ; genetics ; Pedigree ; Syndactyly ; genetics ; Zinc Finger Protein Gli3 ; genetics
4.Application of droplet digital PCR for non-invasive prenatal diagnosis of single gene disease in two families.
Peiwen XU ; Yang ZOU ; Jie LI ; Sexin HUANG ; Ming GAO ; Ranran KANG ; Hongqiang XIE ; Lijuan WANG ; Junhao YAN ; Yuan GAO
Chinese Journal of Medical Genetics 2018;35(2):224-227
OBJECTIVETo assess the value of droplet digital PCR (ddPCR) for non-invasive prenatal diagnosis of single gene disease in two families.
METHODSPaternal mutation in cell-free DNA derived from the maternal blood and amniotic fluid DNA was detected by ddPCR. Suspected mutation in the amniotic fluid DNA was verified with Sanger sequencing.
RESULTSThe result of ddPCR and Sanger sequencing indicated that the fetuses have carried pathogenic mutations from the paternal side in both families.
CONCLUSIONDroplet digital PCR can accurately detect paternal mutation carried by the fetus, and it is sensitive and reliable for analyzing trace samples. This method may be applied for the diagnosis of single gene diseases caused by paternal mutation using peripheral blood sample derived from the mother.
Fathers ; Female ; Genetic Diseases, Inborn ; diagnosis ; Humans ; Male ; Maternal Serum Screening Tests ; Mutation ; Polymerase Chain Reaction ; methods ; Prenatal Diagnosis ; methods ; Sequence Analysis, DNA
5.Novel mutations of XPC gene detected in a family affected with xeroderma pigmentosum group C.
Lijuan WANG ; Sexin HUANG ; Jie LI ; Yang ZOU ; Peiwen XU ; Ming GAO ; Ranran KANG ; Hongqiang XIE ; Xianda WEI ; Yuping NIU ; Xiaowei LIU ; Yuan GAO
Chinese Journal of Medical Genetics 2018;35(4):540-543
OBJECTIVETo detect mutations of the XPC (XPC complex subunit, DNA damage recognition and repair factor) gene in a family affected with xeroderma pigmentosum group C (XP-C).
METHODSThe patient was subjected to next-generation sequencing and Sanger sequencing. Suspected mutations were validated by Sanger sequencing. Effect of splicing mutation was confirmed by reverse transcription-PCR (RT-PCR).
RESULTSCompound heterozygous mutations of c.2098G to T and c.2034-7_2040del were found in the XPC gene in the proband. Among these, c.2098G to T (p.G700X) is a nonsense mutation resulting in a truncated XPC protein. C.2034-7_2040del involves the -1 position, which may alter the splice donor site of the intron 11 of XPC and result in a truncated XPC protein with loss of amino acids from 940 to 679 positions. The two mutations were not detected among 100 unrelated healthy controls.
CONCLUSIONMutations of c.2098 G to T and c.2034-7_2040del of the XPC gene may lead to abnormal XPC expression and reduction or elimination of normal XPC functions, which may underlie the disease in this family.
6.Identification of a novel variant of COL4A5 gene in a pedigree affected with Alport syndrome.
Xiaowei LIU ; Ming GAO ; Yang ZOU ; Lijuan WANG ; Ranran KANG ; Peiwen XU ; Yuping NIU ; Sexin HUANG ; Jie LI ; Hongqiang XIE ; Yuan GAO
Chinese Journal of Medical Genetics 2020;37(8):807-810
OBJECTIVE:
To explore the genetic basis for a pedigree affected with Alport syndrome.
METHODS:
Next generation sequencing and Sanger sequencing was carried out to detect potential variant of the COL4A5 gene among members from the pedigree and 100 unrelated healthy controls.
RESULTS:
A novel missense c.3293G>T (p.Gly1098Val) variant was found in the COL4A5 gene among 6 affected members but not the unaffected members of the pedigree or the 100 healthy controls. According to the American College of Medical Genetics and Genomics standards and guidelines, the c.3293G>T variant was classified as pathogenic (PP1-strong+PM1+PM2+PP3+PP4).
CONCLUSION
By destructing the Gly-X-Y structure of its protein product, the c.3293G>T variant of the COL4A5 gene probably underlies the Alport syndrome in this pedigree. Above finding has enriched the spectrum of COL4A5 variants.
7.Identification of a novel splicing variant of IDS gene in a pedigree affected with type II glycosaminoglycan product storage disease.
Hongqiang XIE ; Lijuan WANG ; Sexin HUANG ; Jie LI ; Yang ZOU ; Peiwen XU ; Ming GAO ; Ranran KANG ; Yuping NIU ; Xiaowei LIU ; Yuan GAO
Chinese Journal of Medical Genetics 2020;37(7):713-716
OBJECTIVE:
To analyze variant of IDS gene in a pedigree affected with mucopolysaccharidosis type II (MPS II).
METHODS:
The proband was subjected to next generation sequencing and Sanger sequencing to identify potential variants. Suspected variant was analyzed by its co-segregation with the disease in the pedigree. Its impact on mRNA splicing was analyzed by using reverse transcription PCR (RT-PCR).
RESULTS:
A hemizygous IVS1-3T>G variant was found in the IDS gene in the proband. RT-PCR results revealed two abnormal cDNA fragments of 600 bp and 300 bp. The 600 bp fragment had inserted 216 nucleotides at the 3' end of intron 1, while the 300 bp fragment had lost 109 nucleotides at the 5' end of exon 2, which resulted in two truncated proteins comprising 38 and 92 amino acids, respectively, instead of the normal product (550 amino acids). The proband and his mother were respectively hemizygous and heterozygous for the variant. The same variant was not found among 100 normal controls.
CONCLUSION
The IVS1-3T>G variant of the IDS gene probably underlies the MPS II in this pedigree by causing reduction or elimination of the IDS protein.
8.Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Xueying LI ; He HUANG ; Bing XU ; Hongqiang GUO ; Yingcheng LIN ; Sheng YE ; Jiqun YI ; Wenyu LI ; Xiangyuan WU ; Wei WANG ; Hongyu ZHAN ; Derong XIE ; Jiewen PENG ; Yabing CAO ; Xingxiang PU ; Chengcheng GUO ; Huangming HONG ; Zhao WANG ; Xiaojie FANG ; Yong ZHOU ; Suxia LIN ; Qing LIU ; Tongyu LIN
Cancer Research and Treatment 2019;51(3):919-932
PURPOSE: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell lymphoma (DLBCL). It is unknown whether the dose-dense R-CHOP (R-CHOP-14) could improve the outcome of the disease in Asian population. MATERIALS AND METHODS: Newly diagnosed DLBCL patients were centrally, randomly assigned (1:1) to receive R-CHOP-14 or R-CHOP-21. R-CHOP-14 was administered every 2 weeks, and R-CHOP-21 was administered every 3 weeks. Primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS), progression-free survival (PFS), response rate and toxicities. RESULTS: Seven hundred and two patients were randomly assigned to receive R-CHOP-14 (n=349) or R-CHOP-21 (n=353). With a median follow-up of 45.6 months, the two groups did not differ significantly in 3-year DFS (79.6% for R-CHOP-14 vs. 83.2% for R-CHOP-21, p=0.311), 3-year OS (77.5% for R-CHOP-14 vs. 77.6% for R-CHOP-21, p=0.903), or 3-year PFS (63.2% for R-CHOP-14 vs. 66.1% for R-CHOP-21, p=0.447). Patients with an International Prognostic Index (IPI) score ≥ 2 had a poorer prognosis compared to those with an IPI score < 2. Grade 3/4 hematologic and non-hematologic toxicities were manageable and similar between R-CHOP-14 and R-CHOP-21. CONCLUSION: R-CHOP-14 did not improve the outcome of DLBCL compared to R-CHOP-21 in Asian population. With manageable and similar toxicities, both of the two regimens were suitable for Asian DLBCL patients. For high-risk patients with IPI ≥ 2, new combination regimens based on R-CHOP deserve further investigation to improve efficacy.
Asian Continental Ancestry Group
;
B-Lymphocytes
;
Cyclophosphamide
;
Disease-Free Survival
;
Doxorubicin
;
Follow-Up Studies
;
Humans
;
Lymphoma, B-Cell
;
Prednisone
;
Prognosis
;
Rituximab
;
Vincristine